BioElectron Technology Corporation

PTC Therapeutics, Inc. ’s CEO Matthew Klein “is thinking about focus.” Klein recently discontinued the company’s preclinical gene therapy programs, reducing residual operating expenses by roughly 15%

A US Food and Drug Administration scientific workshop on mitochondrial diseases signaled the agency’s continued interest in helping drug developers get to the first approvals in disorders like Barth s

Ferroptosis is hot: a rudimentary search of PubMed shows the number of publications referencing “ferroptosis” and “cancer” rising steadily, from 20 papers in 2015 to 46 in 2016, 56 in 2017, 91 in 20

Newron Pharmaceuticals SPA will target its second drug approval in 2018 – following on from the success of its partnered Parkinson's disease therapy Xadago (safinamide) – but this time the company